RE:RE:anyone here anymore? anyone care?the stock has been trending up lately on good volume. ph 1 data should be out this year. also, mrk mentioned that this type of drug may have multiple indications which is a positive for blusf:
From an analyst report, "MRK’s chronic cough drug (MK-7264; P2X3 inhibitor) has moved to Phase III. Dysgeusia (e.g. altered taste perception) was seen in Phase II, but the company has done careful dose optimization/titration work to reduce this side effect. Patients with chronic cough can deal with this condition for years. Looking beyond chronic cough, MRK envisions that the P2X3 inhibitor pathway can also be useful in acute cough, pain, migraine, endometriosis, and possibly IPF."